Inspection Data Reveals US/EU Mutual Recognition Agreement's Impact On China and India
Executive Summary
The agreement reached in the early days of the Trump administration has been putting China and India drug manufacturing in the crosshairs of the world’s leading pharmaceutical inspectorates.
You may also be interested in...
Woodcock Touts Baby Steps Toward Global Manufacturing Quality Dossier
Focus of the campaign is the well-established pharmaceutical manufacturing sector, rather than cell and gene therapy production, the US FDA’s principal deputy commissioner said.
Lachman CEO On Compliance And Living The Code Of Conduct
Frances Zipp, president and CEO of Lachman Consultant Services, Inc, in an interview with Scrip, emphasizes the importance of the ‘cultural element’ and top management engagement in addressing compliance issues, including those pertaining to data integrity, at Indian firms.
EMA Drops 130 US Manufacturing Site Inspections Under Landmark MRA
The European Medicines Agency says it is too early to speculate on when the EU will recognize the first US Food and Drug Administration inspection under the mutual recognition agreement signed last year.